ArticleRadiation oncology (London, England)2019
Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas.
Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline.Radiation oncology (London, England) · 2023Guideline
- Hypofractionated stereotactic radiation therapy for optic nerve sheath meningiomas: A single-center experience and preliminary results.Radiation oncology (London, England) · 2026Article
- Dosimetric evaluation of a novel automated noncoplanar volumetric modulated arc therapy technique for treating optic nerve sheath meningiomas.Frontiers in oncology · 2025Article
- Radiation therapy for optic nerve sheath meningiomas: Local control and treatment related visual changes.World neurosurgery: X · 2024Article
- Role of hypofractionated stereotactic radiotherapy for primary optic nerve sheath meningioma.Neuro-oncology practice · 2024Article
- The treatment efficacy of radiotherapy for optic nerve sheath meningioma.Eye (London, England) · 2024Article
- Stereotactic intensity-modulated radiotherapy for skull base meningioma using the HybridArc with Novalis STx system.Surgical neurology international · 2023Article
- Long-Term Visual Function After Fractionated Stereotactic Radiotherapy for Primary Optic Nerve Sheath Meningioma: A Retrospective Analysis of 34 Subjects.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Treatment of Recurrent Optic Nerve Sheath Meningioma With a Secondary Course of Radiotherapy.Cureus · 2021Article
- Article
- Effectiveness and Safety of Robotic Radiosurgery for Optic Nerve Sheath Meningiomas: A Single Institution Series.Cancers · 2021Article
- Primary and Secondary Optic Nerve Sheath Meningioma.Journal of neurological surgery. Part B, Skull base · 2021Article
- Article
- Efficacy and Safety of Proton Beam Therapy for Primary Optic Nerve Sheath Meningioma.Eye and brain · 2021Article
- Potential Defects and Improvements of Equivalent Uniform Dose Prediction Model Based on the Analysis of Radiation-Induced Brain Injury.Frontiers in oncology · 2021Article
- Correction to: Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas.Radiation oncology (London, England) · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAs optic nerve sheath meningiomas (ONSM) are rare, there are no prospective studies. Our retrospective analysis focusses on a cohort of patients with uniform disease characteristics all treated with the same radiotherapy regimen. We describe treatment decision making, radiotherapy planning and detailed neuro-ophthalmological outcome of the patients.
methods26 patients with unilateral ONSM extending only to the orbit and the optic canal were evaluated for neuro-ophthalmological outcome. Radiation treatment was planned in a simultaneous integrated boost approach to gross tumor volume (GTV) + 2 mm / 5 mm to 54 Gy / 51 Gy in 1.8 Gy / 1.7 Gy fractions. Follow-up was done by specialized neuro-ophthalmologists. Visual acuity and visual field defects were evaluated after therapy as well as during follow-up.
resultsInterdisciplinary treatment decision for patients with ONSM follows a rather complex decision tree. Radiation treatment planning (equivalent uniform dose (EUD), maximum dose to the optic nerve) improved with experience over time. With this patient selection visual acuity as well as visual field improved significantly at first follow-up after treatment. For visual acuity this also applied to patients with severe defects before treatment. Long term evaluation showed 16 patients with improved visual function, 6 were stable, in 4 patients visual function declined. Interdisciplinary case discussion rated the visual decline as radiation-associated in two patients.
conclusionsWith stringent patient selection radiotherapy for unilateral primary ONSM to 51 Gy / 54 Gy is safe and leads to significantly improved visual function. Interdisciplinary treatment decision and experience of the radiation oncology team play a major role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.